Catherine Coombs, MD, Talks Challenges with BTK Inhibitors in CLL Treatment
By Leah Sherwood - Last Updated: February 1, 2023In this second video interview with Catherine Coombs, MD, during the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), she discusses some of the challenges remaining with Bruton’s tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL) treatment.
Advertisement
Post Tags:SOHO 2022
Advertisement
Related Posts
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.